India’s Biological E to Shoulder Manufacturing

Hyderabad-based Biological E will be the partner manufacturer in the vaccine initiative launched by the Quad group of countries in its first summit level meeting on Friday. For now Johnson and Johnson’s Covid-19 vaccine has been identified, among other US developed vaccines, by the US International Development Finance Corporation (DFC) to be manufactured in India with an aim to reach the one billion doses by end of 2022.

Biological E is a woman-run and woman-operated business “advancing DFC’s 2X Women’s Initiative to promote global gender equity,” said the press release from US DFC. Biological E was established in 1953 and is headed by Mahima Datla — the managing director and CEO of the company.

The agency seeks to invest between $5 million and $500 million per eligible project through its full range of financial tools, which includes equity and debt financing, political risk insurance and technical development.

The DFC is America’s development bank. DFC partners with…

Exit mobile version